# Metformin Use and Development of Esophageal Squamous Cell Carcinoma

## TL;DR

Metformin use is linked to a 36% lower risk of developing esophageal squamous cell carcinoma, especially at higher doses.

## Contribution

This large Nordic case-control study provides new evidence that metformin may reduce the risk of ESCC.

## Key findings

- Metformin use was associated with 36% lower odds of ESCC compared to nonuse.
- Higher metformin dosage was linked to even greater risk reduction (52% lower odds).

## Abstract

Dose use of metformin reduce the risk of developing esophageal squamous cell carcinoma (ESCC)?

In this case-control study with 13 050 patients with ESCC and 130 500 control participants, metformin use was associated with 36% lower odds of ESCC. This was more profound among high-dosage users.

These findings suggest metformin use may have preventive potential against ESCC, which warrants further evaluation.

This case-control study investigates potential associations between the use of metformin and risk of esophageal squamous cell carcinoma in Denmark, Finland, Iceland, Norway, and Sweden.

Esophageal squamous cell carcinoma (ESCC) carries a poor prognosis, stressing the need for preventive measures. A decreased risk of ESCC among metformin users has been suggested, but evidence is limited.

To assess whether metformin use, given its potential anticancer properties, is associated with risk of ESCC.

This population-based case-control study set between 1994 and 2023 looked at data from all 5 Nordic countries (ie, Denmark, Finland, Iceland, Norway, and Sweden). Participants were patients newly diagnosed with ESCC during the study period, and each was compared with 10 times as many control participants randomly selected from the general population (matched by age, sex, calendar year, and country).

Use of metformin vs nonuse.

Conditional logistic regression provided odds ratios (OR) with 95% CIs for the association between metformin use and the development of ESCC. In addition to the matching, the ORs were adjusted for tobacco smoking, alcohol overconsumption, use of nonsteroidal anti-inflammatory drugs or aspirin, and use of statins. A dose-response analysis was conducted among participants with at least 5 years of observation time, based on the defined daily dose during the 5-year period.

This study included 13 050 case patients with ESCC (8030 men [61.5%] and 5020 women [38.5%], diagnosed at a median age of 70 years [IQR, 62-77 years]), and 130 500 age- and sex-matched control participants. Metformin use was associated with a 36% lower odds of ESCC compared with nonuse (OR, 0.64; 95% CI, 0.59-0.69). The odds were especially lower in participants with a higher dosage of metformin (>1278 defined daily dose in 5 years: OR, 0.52; 95% CI, 0.44-0.61).

In this case-control study, metformin use was associated with substantially lower odds of ESCC. This finding should prompt investigations of metformin as a preventive option in high-risk individuals and as a potential future therapeutic agent for ESCC.